To make things easier, leave this box checked On shared devices, we recommend that you disconnect from Euroquity when you are done
Email

You will receive an email to define a new password

Location

Select your country

and your language

Hi ,

Welcome to your personnel profile page! Fill in your information in order to become more visible to organizations that interest you.

% completed

%

medal 1
This profile is validated by 1 label.

Company

REMEDOR BIOMED LTD

REMEDOR BIOMED LTD_logo
15
EQ SCORE

The EQ Score shows the company's activity and appeal on the platform: profile completeness, news, likes, follows, membership in one or more labels or communities, number of members in its network, etc.

Our cutting-edge innovation aims to provide the first EMA-approved pharmaceutical solution for Diabetic Foot Ulcer treatment.

Nazareth, North, Israel

Send a message

English

REMEDOR BIOMED LTD

English

Diabetes is a global epidemic with currently more than 460 million people worldwide living with diabetes and this number is fast growing. It is estimated that > 75 million diabetic patients globally are at high risk of developing diabetic foot ulcer (DFU) complications. Currently, about 26 million people live with non-healing DFUs globally and 1 in 5 individuals with DFUs will require a limb amputation and these patients will require a subsequent amputation within 5 years. Mortality...

See more

Diabetes is a global epidemic with currently more than 460 million people worldwide living with diabetes and this number is fast growing. It is estimated that > 75 million diabetic patients globally are at high risk of developing diabetic foot ulcer (DFU) complications. Currently, about 26 million people live with non-healing DFUs globally and 1 in 5 individuals with DFUs will require a limb amputation and these patients will require a subsequent amputation within 5 years. Mortality among diabetic patients with a DFU is 2.5 times higher than that of a diabetic patient without a DFU. After an amputation, an individual may not get out of bed much in the following months, or even years, leading to overall health deterioration and, ultimately culminating in death from associated stroke or heart attack. Despite the devastating effect of DFUs and the massive costs they incur on the healthcare systems, there are still no pharmaceutical products that accelerate DFU healing safely and cost-effectively. To address the DFU problem, we developed a safe and cost-effective solution based on a globally patented “smart” topical hydrogel that accelerates DFU healing. Our cutting-edge innovation aims to provide the first EMA-approved pharmaceutical solution for DFU treatment. We delivered and published our remarkable results of phase 1/2a clinical trial, and we are now preparing for a phase 2b clinical trial in pursuit of marketing authorization of our flagship product.

Team member(s)

Your request has been sent
Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

InvestHorizon - Accelerated
The InvestHorizon Accelerated label is for selected deep tech companies from the accelerator programme to facilitate series A funding.  This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential. InvestHorizon is a programme financed by the European Commission in association with Eureka to foster investment readiness.
454 Entities

Communities

InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
2672 Members